Reporting : Final Progress Report Instructions for NHLBI Grantees.
Professional Advisory Services for NHLBI Small Business Companies/ Grantees
Not sure about how to make contact with the FDA? Wondering about how to protect your intellectual property? Need advice on your commercialization plan? The Office of Translational Alliances and Coordination has brought together a team of experts skilled in Regulatory Affairs, Intellectual Property, and Business Development. Visit the OTAC Resources Page for further information on these topics and contact us to schedule a meeting.
Commercialization Assistance Program
The NIH Commercialization Assistance Program (CAP) is a FREE specialized technical assistance program for SBIR Phase II awardees. CAP is designed to help promising small life science companies develop their commercial businesses and transition their SBIR-developed technologies into the marketplace. CAP applications are accepted once per year, usually in the Fall. We will post more information here when the program is again selecting applications.
Niche Assessment Program
The NIH SBIR Niche Assessment Program is a FREE nationwide program funded by the NIH to help jump-start an SBIR Phase I awardee's commercialization efforts. Services are provided by Foresight Science and Technology of Providence, RI.
Technology Niche Analyses™ (TNA™) are provided by Foresight for one hundred (100) NIH SBIR Phase I awardees. These analyses assess potential applications for a technology and then for one viable application, it provides an assessment of the:
- needs and concerns of end-users;
- competing technologies and competing products;
- competitive advantage of the SBIR-developed technology;
- market size and potential market share (may include national and/or global markets);
- barriers to market entry (may include but are not limited to pricing, competition, government regulations, manufacturing challenges, capital requirements, etc.);
- market drivers;
- status of market and industry trends;
- potential customers, licensees, investors, or other commercialization partners; and,
- the price customers are likely to pay
The FDA provides the following education materials:
For more Regulatory information, please visit the OTAC Resources Page.
For more IP information, please visit the OTAC Resources Page.
Last Updated March 2016